Dr Susan Short


Personal Profile

Name: Susan Short Email: s.short@ucl.ac.uk
Title: Dr Tel: 020 7679 6471
Department: Research Department of Oncology Fax: 020 7679 6925
Position: Honorary Senior Lecturer Address: Paul O'Gorman Building, 72 Huntley St, London, WC1E 6BT
Research Domain: Cancer, Personalised Medicine Web Page: Personal Web Page


Research Description

The aim of our current work is to investigate novel means of selective radiosensitisation of relevant tumour cell populations in high grade glioma. We plan to define the repair phenotype of glioma stem cells, neuronal stem cells and differentiated cells derived from these cell types and assess their response to different combination treatments using in vitro and in relevant in vivo models. These data will establish which approaches may lead to improved local control of glioma without increased long-term toxicity in the context of technically advanced radiotherapy treatment.

Research Activities

Homologous recombination: processing of Holliday junctions and repair complexes.

Low-grade gliomas and paraneoplastic disorders


Education Description

National and international radiation biology courses for clinicians and scientists Royal College of radiologists fellowship courses for clinical oncology trainees Oncology modules for UCL medical school students

UCL Collaborators

External Collaborators



    • Short SC, Giampieri S, Worku M, German M, Sioftanos G, Bourne S (2011). Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumour derived cells.. Neuro-Oncology, 13(5), 487 - 499.
    • Sivabalasingham S, Fersht N, D'Souza D, Rosenberg I, Stacey C, Davies P, Guerro-Urbano T, Short S (2011). Preliminary Results from a Phase I/II Study of Intensity Modulated Radiotherapy in the Treatment of Meningiomas. CLIN ONCOL-UK, 23(3), S53 - S53.


    • Ella W, Short SC (2009). Using retinoids to increase radio-iodine uptake in thyroid cancer: role as potential redifferentiation agents. In (Ed.), The handbook on iodine (pp. - ). : Elsevier.
    • Short SC (2009). Re-irradiation of brain tumours-evidence, indications and limitations.
    • Hall JRAS, SC (2009). Management of Glioblastoma Multiforme in HIV patients: a case series and review of published studies. Clinical Oncology, , - .
    • Rees J, Brandner S, Howard R, J├Ąger HR, Short S, Thomas DT, E Z, G (2009). Neuro-oncology. In Clarke C, Howard R, Rossor M, Shorvon S (Ed.), Neurology: A Queen Square textbook (pp. 771 - 822). : Wiley-Blackwell.


    • Short S, C (2008). Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer, , - .
    • Taylor R, Pizer B, Short S (2008). Promoting collaboration between adult and paediatric study groups. Clinical Oncology, 20(9), 714 - 716.


    • Short SC, Martindale C, Bourne SM, Brand G, Woodcock M, Johnston P (2007). Damage signalling after TMZ and radiation in glioma cells and sensitisation by inhibition of repair in G2.
    • Short SC, Buffa FM, Bourne S, Koritzinsky M, Wouters BG, Bentzen SM (2007). Dose- and time-dependent changes in gene expression in human glioma cells after low radiation doses. RADIATION RESEARCH, 168(2), 199 - 208. doi:10.1667/RR0940.1
    • Burdak-Rothkamm S, Short S, Folkard M, Rothkamm K, Prise KM (2007). ATR-Dependent Radiation Induced g-H2AX Foci In Bystander Primary Human Astrocytes And Glioma Cells.. Oncogene, 26(7), 993 - 1002. doi:10.1038/sj.onc.1209863
    • Short SC, Martindale C, Bourne S, Brand J, Johnston P (2007). DNA damage response in gliomas and normal human astrocytes. Neuro-Oncology, 9(4), 404 - 411.


    • Short SC, Bourne S, Martindale C, Johnston P (2006). DNA repair after clinical radiation doses in gliomas and normal human astrocytes.
    • Shanley S, McReynolds K, Ardern JA, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E1, Pierce L, Short S, Gui GATBUOTRMHT, Barr L, Baildam A, Howell T, Royle G, Easton DAER (2006). Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clinical Cancer Research, 1(12), 7025 - 7032.
    • Short S (2006). BBC 6 O'Clock news.
    • Brooks S, Daley F, Johns P, Brandner S, Short SC (2006). Pescadillo and CYP1B1: Novel metabolic targets in glioma.
    • Shanley SBKS, S Evans G Tutt AH, S Powles TASA, R Easton D and Eeles R (2006). Acute Chemotherapy related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the UK.. Clinical Cancer Research, , - .


    • Lee M, Mahroof S, Pringle J, Short SC, Briggs TWR, Cannon SR (2005). Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy. INTERNATIONAL ORTHOPAEDICS, 29(6), 403 - 405.
    • Short S, Buffa F, Koritzinsky M, Wouters B, Bentzen SM (2005). Radiation induced changes in gene expression in human glioma cells.
    • Krause M, Wohlfarth J, Georgi B, Pimentel N, Dorner D, Zips D, Eicheler W, Hessel F, Short SC, Joiner MC, Baumann M (2005). Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 81(10), 751 - 758.
    • Short S, Bourne S, Martindale C, Woodcock M, Jackson SP (2005). DNA damage responses at low radiation doses.. Radiation Research, 164(3), 292 - 302. doi:10.1667/RR3421.1


    • Harney J, Short S, Shah N, Joiner M, Saunders MI (2004). Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics, 59(4), 1190 - 1195. doi:10.1016/j.ijrobp.2003.12.029
    • Harney J, Shah N, Short S, Daley F, Groom N, Wilson GD, Joiner MC, Saunders MI (2004). The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiotherapy and Oncology, 70(3), 319 - 329. doi:10.1016/j.radonc.2004.01.015
    • Litchfield TM, Gilchrist S, Sunderland R, Folkard M, Short S, Prise K (2004). A three dimensional tissue culture model for microbeam studies.
    • Short SC, Suovuori A, Cook G, Vivian G, Harmer C (2004). A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clinical Oncology, 16(8), 569 - 574.


    • Harney J, Shah N, Short S, Saunders M, Joiner M (2003). Low dose hyper-radiosensitivity-a clinical assessment.
    • Redpath JL, Short SC, Woodcock M, Johnston P (2003). Low dose reduction in transformation frequency compared to unirradiated controls: the role of hyper-radiosensitivity. Radiation Research, 159, 433 - 436.
    • Short S, C H, J (2003). Radiobiology and vascular targeting in glioma. Current opinion in neurology, 16, 651 - 655.
    • Krause M, Hessel F, Wohlfarth J, Zips D, Hoinkis C, Foest H, Short S, C J, M C, Baumann M (2003). Ultrafractionation in A7 malignant glioma in nude mice. , 79(6), 377 - 383.
    • Short S, Buffa F, Bourne S, Johnston P, Bentzen S (2003). Determining dose response relationships of gene expression in human tumour cells after low radiation doses using micro-array analysis.
    • Short S (2003). External beam and conformal radiotherapy in the management of gliomas. In Westphal (Ed.), Local therapies for glioma (pp. - ). : Springer.


    • Kirkby N, Faraday DBF, Short S, C W, M J, M C B, N G (2002). Mathematical modelling to develop a novel radiotherapy schedule for high grade brain tumours, based on phase distribution of low-dose hypersensitivity in human glioma cell lines.
    • Harney J, Shah N, Short SC, Joiner M, Saunders MI (2002). Low dose hyper-radiosensitivity - does it exist in normal skin?.
    • Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M (2002). Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology, 57(3), 247 - 251.
    • Harney J, Short SC, Saunders MI (2002). Low dose hyper-radiosensitivity - A clinical assessment.
    • Short SC, Harney J, Dopson F, Saunders MI (2002). The effects of low-dose fractionated radiation on sarcomas- experimental and clinical data. British Journal of Cancer, 86, S56 - S57.
    • Harney J, Shah N, Joiner M, Short S, Saunders MI (2002). Low dose hyper-sensitivity- does it occur in normal skin?.


    • Short SC, Brada M (2001). The treatment of malignant celebral tumours. Hospital Medicine, 61(11), 772 - 777.
    • Short SC, Kelly J, mayes CR, Woodcock M, Joiner MC (2001). Low-dose hypersensitivity after fractionated low-dose irradiation. International journal of radiation biology, 77(6), 655 - 664.
    • Short S (2001). Thalidomide as an anti-angiogenic agent in recurrent gliomas. Journal of Neuro-Oncology, 51, 41 - 55.
    • Nutting C, Short S (2001). Where now with training in clinical oncology?. Clinical Oncology, 13, 4 - 5.
    • Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M (2001). Thalidomide as an anti-angiogenic agent in relapsed gliomas. Journal of Neuro-Oncology, 51(1), 41 - 45.


    • Joiner M, Short S, Mayes C, Lambin P, Marples B, Shah N, Saunders MI (2000). Low dose hypersensitivity and induced radioresistance: Possibilities for therapy and implications for radioprotection. International Journal of Radiation Oncology Biology Physics, 46(3), 692 - 692.
    • Short S, C B, M (2000). The treatment of malignant cerebral tumours. Hospital Medicine, 61(11), 772 - 777.


    • Joiner MC, Marples B, Lambin P, Short S, Turesson I (1999). Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics, 49(2), 379 - 389.
    • Short S (1999). The response of human glioma cells to low dose radiation. International journal of radiation biology, 75, 1341 - 1348.
    • Short S, Mayes C, Woodcock M, Joiner MC (1999). Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology, 75, 847 - 855.


    • Gerrard G, Short S, C (1998). The future of oncology training from the trainees' perspective. Clinical Oncology, 10, 84 - 91.
    • Short S, C J, M (1998). Cellular response to low-dose irradiation. Clinical Oncology, 10, 73 - 78.


    • Short S, Chatterverdi A, Leslie M (1996). The treatment of adrenal metastases. Clinical Oncology, 8, 387 - 389.


    • Abbott D, Bleakman N, Short S (1986). Glucose transport across the glial blood-brain barrier of the cuttlefish Sepia.

    • Chalmers AJ, Lovegrove , N , Ruff E, Martindale C, Short , SC (). Cytotoxicity of radiation and temozolomide is additive and schedule dependent. International Journal of Radiation Oncology Biology Physics, , - .